Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Trial aims to crack the code on drug sequencing for tough breast cancers

NCT ID NCT07162259

Not yet recruiting Disease control Sponsor: Yan Xue Source: ClinicalTrials.gov ↗

Summary

This study aims to find the best order to use two newer, targeted cancer drugs (called ADCs) for people with advanced breast cancer that has stopped responding to standard hormone-based treatment. It will follow 40 patients in real-world clinics to see which drug sequence works better to control the cancer for longer and is safer. The goal is to gather evidence to help doctors make more precise treatment decisions for their patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Xi'an International Medical Center Hospital

    Xi'an, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.